Bicara Therapeutics (BCAX) Net Equity Issued and Repurchased (2024 - 2026)

Bicara Therapeutics' Net Equity Issued and Repurchased history runs 3 years deep, the most recent figure standing at $161.8 million for Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $161.8 million in Q1 2026; TTM through Mar 2026 was $190.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $29.5 million, down 91.13% from the prior year.
• Net Equity Issued and Repurchased rose to $161.8 million in Q1 2026 per BCAX's latest filing, from $29.5 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $161.8 million in Q1 2026 and bottomed at -$1.1 million in Q4 2024.
• The 3-year median for Net Equity Issued and Repurchased is $29.5 million (2025), against an average of $63.4 million.
• Biggest YoY gain for Net Equity Issued and Repurchased was 2903.99% in 2025; the steepest drop was 2903.99% in 2025.
• Year by year, Net Equity Issued and Repurchased stood at -$1.1 million in 2024, then jumped by 2903.99% to $29.5 million in 2025, then soared by 448.39% to $161.8 million in 2026.
• Per Business Quant, the three latest BCAX Net Equity Issued and Repurchased figures stand at $161.8 million (Q1 2026), $29.5 million (Q4 2025), and -$1.1 million (Q4 2024).